Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
about
Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3β/β-catenin signaling pathway.A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.Mechanistic and pharmacologic insights on immune checkpoint inhibitors.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccinesImmune Modulation Therapy and Imaging: Workshop Report.Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer.Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy.Immunotherapy for Breast Cancer: What Are We Missing?Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.Contraction of T cell richness in lung cancer brain metastases.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer.Modulation of immunosurveillance by tumor-intrinsic genomic alterations.Tumor immunity and survival as a function of alternative neopeptides in human cancer.Emerging biomarkers for cancer immunotherapy in melanoma.Mechanisms regulating T-cell infiltration and activity in solid tumors.Genetic mechanisms of immune evasion in colorectal cancer.PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in IComplimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration.Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).Biomarkers for Immune Checkpoint Inhibitors in MelanomaExploring optimal sequencing of radiation and immunotherapy combinations
P2860
Q38605933-978E833E-1772-40DD-966E-4922CAD1A778Q38713958-CA2A1106-8AAC-4AEE-8620-05E66E28D5A0Q39190066-91E213C0-390B-4D5C-9924-DF877A24BF4FQ39448911-1283AFF3-189B-48C9-A0BB-7CC49C4C6A84Q40089191-350670FB-ECF1-4F0E-8E2E-2DC98F297A94Q41810793-D347AB3F-1F13-4FE8-A432-1954F3A0AAF4Q41930681-A2DD7E43-4CED-45CB-B38E-6E358EAAEC37Q44668850-3C273E7D-FD46-4376-89D2-31A1F9C8266FQ46721978-34C99CCE-367F-4206-9341-C70FA72D5ACDQ47120629-B3FBE981-5FD6-4217-A612-AE25D999B690Q47134263-DC3772F1-D14C-4E13-B741-06BCB7817AB9Q47292249-7642F80B-36F4-4BFD-AD16-8B7C6659C49AQ47335259-7D32B10D-586F-45E4-BFBB-3B4F1466AFFBQ47666073-B37C9137-06DC-487A-9CFA-293AED4F711BQ47825143-E4619ADE-43BC-4C88-B366-59835C273C63Q48102534-1D39576E-295B-4706-8A50-3412FF389ECCQ48274813-BACC0C2E-D22F-4BCE-9B68-4B42C594E3B6Q49399733-95147111-B554-470A-8CF7-87C14EEB1230Q49557912-05DE49FF-CA2F-451B-91B4-9B307805440BQ50020805-04A0C490-FB9A-4DE7-9E0D-C316F0DF7206Q50058145-5C4819B1-B75A-425E-BCDA-22E9FC812DCFQ50089395-90B3DD8D-0B0C-4C9D-9850-3E3C4A0DA22CQ50420634-174E5761-C7FC-4AD2-8988-25235E1DA218Q52668712-36B9EFAF-4D72-4932-B66A-724725B1AF94Q53827639-8142F571-9CE8-4FF7-AFE8-98BC7A37B887Q54685474-5DB926D6-E238-4AF1-A4B1-1781D9003C4CQ55049458-E868BA4A-98BC-43C6-838D-5CD847DD65AFQ55380684-D1940600-7747-41AC-92D6-3303DB235E41Q55497366-034DC886-0D21-4679-B99F-0D8CB20C694BQ57175477-C11FBDF9-BA84-4B5F-8DE1-CB041AFCBF50Q58119202-60FA96F6-9226-4CB8-84C5-E4BE31CB5423
P2860
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Density of immunogenic antigen ...... microenvironment in melanoma.
@en
Density of immunogenic antigen ...... microenvironment in melanoma.
@nl
type
label
Density of immunogenic antigen ...... microenvironment in melanoma.
@en
Density of immunogenic antigen ...... microenvironment in melanoma.
@nl
prefLabel
Density of immunogenic antigen ...... microenvironment in melanoma.
@en
Density of immunogenic antigen ...... microenvironment in melanoma.
@nl
P2093
P2860
P356
P1476
Density of immunogenic antigen ...... microenvironment in melanoma.
@en
P2093
Alexander P Gajewski
Jason J Luke
Kyle M Hernandez
Thomas F Gajewski
Yuanyuan Zha
P2860
P304
E7759-E7768
P356
10.1073/PNAS.1609376113
P407
P577
2016-11-11T00:00:00Z